Back to search
FDAFDA · Food and drugs·Recall number D-0151-2023

Olopatadine HCl Ophthalmic Solution, USP 0.1%, 5 mL per bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. Marketed by: GSMS, Incorporated, Camarillo, CA 93012. NDC: 60429-957-05

Published January 25, 2023 · Recall initiated: October 13, 2022

Summary

FDA records drug Class II recall D-0151-2023, published January 25, 2023 and initiated October 13, 2022. Recalling firm: Akorn, Inc.; Status: Ongoing; Reported quantity: 121,176 bottles; Lot: Lot: 1C61A, EXP 2/28/2023; 1D86A, 1D07A, EXP 3/31/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations:

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akorn, Inc.
Distributor
Nationwide in the USA
Lot
Lot: 1C61A, EXP 2/28/2023; 1D86A, 1D07A, EXP 3/31/2023;
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Olopatadine HCl Ophthalmic Solution, USP 0.1%, 5 mL per bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. Marketed by: GSMS, Incorporated, Camarillo, CA 93012. NDC: 60429-957-05 recalled?

Yes. FDA published recall D-0151-2023 on January 25, 2023. Reported hazard: CGMP Deviations:

What should I do if I have this product?

Voluntary: Firm initiated · Letter